The influence of treatment sequence in the prognostic value of TMPRSS2‐ERG as biomarker of taxane resistance in castration‐resistant prostate cancer

TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity inPTENandTP53-mutated prostate cancer

(2018) Alexandra M Blee et al.   CLINICAL CANCER RESEARCH

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

(2018) Philipp Nuhn et al.   EUROPEAN UROLOGY

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

(2018) Rahul Aggarwal et al.   JOURNAL OF CLINICAL ONCOLOGY

Cellular plasticity and the neuroendocrine phenotype in prostate cancer

(2018) Alastair H. Davies et al.   Nature Reviews Urology

Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer

(2018) Zhenyu Xu et al.   ONCOGENE

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

(2018) Vincenza Conteduca et al.   EUROPEAN UROLOGY

Significance of the TMPRSS2:ERG gene fusion in prostate cancer

(2017) Zhu Wang et al.   Molecular Medicine Reports

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

(2017) Sheng Yu Ku et al.   SCIENCE

TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer

(2016) Òscar Reig et al.   EUROPEAN UROLOGY

Androgen deprivation modulates gene expression profile along prostate cancer progression

(2016) Marco Volante et al.   HUMAN PATHOLOGY

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

(2016) Howard I. Scher et al.   JAMA Oncology

Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy

(2015) Sujata Narayanan et al.   Nature Reviews Urology

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

(2015) Emmanuel S. Antonarakis et al.   JAMA Oncology

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

(2014) Maria Thadani-Mulero et al.   CANCER RESEARCH

Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer

(2014) M. Marin-Aguilera et al.   MOLECULAR CANCER THERAPEUTICS

ERG induces taxane resistance in castration-resistant prostate cancer

(2014) Giuseppe Galletti et al.   Nature Communications

Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion-Positive Prostate Cancers

(2010) Yu Chen et al.   CANCER CELL

An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression

(2010) Jindan Yu et al.   CANCER CELL

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

(2009) G. Attard et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

(2008) C Sun et al.   ONCOGENE